Feline osteoarthritis (OA) pain management is multimodal, with anti-nerve growth factor (anti-NGF) monoclonal antibodies and NSAIDs as the two analgesic classes with proven efficacy in cats. OA is the primary source of chronic pain in cats, affecting well over a quarter of the feline population, with radiographic degenerative joint disease present in 61–93% of all cats and pain-associated clinical signs estimated in 40% of those cats.Journal of Feli…+1
Frunevetmab, a felinized anti-NGF monoclonal antibody, is the most clinically attractive pharmacologic option for feline OA pain. It is administered as 3 monthly subcutaneous injections, producing positive treatment effects on mobility impairment and disability through 84 days.Journal of Vete… Because it is injectable, it eliminates the need for daily oral dosing — a recognized compliance barrier in cats.Journal of Vete… Adverse events attributable to frunevetmab are limited to skin-related reactions: dermatitis, pruritus, and alopecia.Journal of Vete… The long-term effects of repeated administration and optimal dosing conditions have not yet been fully characterized.Journal of Feli…
NSAIDs remain a cornerstone of feline OA analgesia, though their use carries important caveats. Meloxicam and robenacoxib are approved in parts of the world (not the United States) for chronic musculoskeletal pain in cats.Journal of Vete… Both COX-inhibiting and non-COX-inhibiting NSAIDs (including grapiprant) are recognized analgesic options by the WSAVA.WSAVA Global Gu… Despite evidence of efficacy and a safety profile acceptable in many cats including those with chronic kidney disease, the mechanism of action of this drug class produces adverse effects in some cats, and daily oral administration is problematic for many owners regardless of formulation.Journal of Vete…
Acetaminophen (paracetamol) is contraindicated in cats. The WSAVA explicitly excludes it from feline analgesic options.WSAVA Global Gu…
Non-pharmacologic modalities are recommended as part of a multimodal plan, including weight control, therapeutic exercise, physiotherapy, laser therapy, acupuncture, massage, transcutaneous electrical nerve stimulation, and joint mobilization.WSAVA Global Gu… However, evidence supporting these modalities in cats specifically is limited — most data are extrapolated from human medicine or other veterinary species, introducing a high risk of bias.Journal of Feli…
Pain assessment should incorporate owner-completed clinical metrology instruments (CMIs), as clinic-based orthopedic examination is unreliable in cats due to stress responses, bilateral joint involvement, and the absence of single-limb lameness as a consistent sign.Veterinary Reco… The Feline Musculoskeletal Pain Index (FMPI) has undergone the most extensive validity and reliability testing and is recommended for clinical use.Veterinary Reco…
| Drug/Modality | Protocol | Efficacy | Key Caveat |
|---|---|---|---|
| Frunevetmab (anti-NGF mAb) | 3 monthly SC injections | Positive effects on mobility and disability through 84 days | Long-term repeated dosing effects not yet characterized |
| Meloxicam / Robenacoxib (NSAIDs) | Oral, chronic use | Proven efficacy for DJD/OA pain | Not US-approved for chronic use; adverse effects in some cats; daily oral dosing compliance issues |
| Grapiprant (non-COX NSAID) | Oral | Recognized analgesic option | Limited feline-specific data in sources |
| Acetaminophen | — | — | Contraindicated in cats |
| Non-pharmacologic (weight loss, physiotherapy, laser, acupuncture, TENS) | Multimodal adjuncts | Supportive; evidence largely extrapolated from humans/other species | High risk of bias for feline-specific conclusions |
Would you like to go deeper on frunevetmab dosing, monitoring, and how to sequence it with NSAIDs in cats that have already been on chronic meloxicam?